Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Sathler Avelar, Renato ^a,b,c,d   Vitelli Avelar, Danielle M ^a,d   Elói Santos, Silvana M ^d   Gontijo, Eliane D ^d   Teixeira Carvalho, Andréa ^a,d   Martins Filho, Olindo A ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Newton Paiva University   (Brazil)

^c Universidade Vale do Rio Verde   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Benznidazole; Chagas disease; Cytokines; Immune response; Leucocytes subsets

Indexed keywords

BENZNIDAZOLE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; PARASITE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; LEUKOCYTE; MALE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; TRYPANOSOMA CRUZI;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NITROIMIDAZOLES; TH1 CELLS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 84861334052     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-123     Document Type: Article

References (34)

1. World Health Organization New global effort to eliminate Chagas disease. Weekly Epidemiol Rec 2007, 82:259-260. World Health Organization.
2. Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, Reis D, Gollob KJ. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 2009, 104:208-218.
3. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009, 104:311-318.
4. de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996, 343:1407-1413.
5. Secretaria de Vigilância em Saúde do Ministério da Saúde Consenso brasileiro em doença de Chagas. Revista Soc Bras Med Trop 38:1-29. Secretaria de Vigilância em Saúde do Ministério da Saúde.
6. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. AmJTrop Med Hyg 1998, 59:526-529.
7. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005, 49:1521-1528.
8. Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006, 19:583-587.
9. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
10. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009, 64:1139-1147.
11. Michailowsky V, Murta SM, Carvalho-Oliveira L, Pereira ME, Ferreira LR, Brener Z, Romanha AJ, Gazzinelli RT. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother 1998, 42:2549-2556.
12. Rassi A, Amato Neto V, de Siqueira AF, Ferriolli Filho F, Amato VS, Rassi Júnior A. Protective effect of benznidazole against parasite reactivation in patients hronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases. Rev Soc Bras Med Trop 1999, 32:475-482.
13. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, de Lana M, Pinto Dias JC, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho AO. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. Microbes Infect 2008, 10:103-113.
14. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol 2006, 64:554-563.
15. Fundação Nacional de Saúde Tratamento etiológico da doença de Chagas-Brasília. Coordenação de controle de doenças transmitidas por vetores-gerência técnica de doença de Chagas Fundação Nacional de Saúde, Rio de Janeiro, Brazil, 2, 32, Fundação Nacional de Saúde.
16. Lowry OH, Rosenbrough M, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
17. Bahia-Oliveira LM, Gomes JA, Rocha MO, Moreira MC, Lemos EM, Luz ZM, Pereira ME, Coffman RL, Dias JC, Cançado JR, Gazzinelli G, Corrêa-Oliveira R. IFN-gamma in human Chagas' disease: protection or pathology?. Braz J Med Biol Res 1998, 31:127-131.
18. Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, Pinto Dias JC, Gontijo ED, Faria AM, Elói-Santos SM, Martins-Filho OA. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol 2008, 68:516-525.
19. Mazza S, Montana A, Benitez C, Janzi EZ. Transmission del Schizotrypanum cruzi al niño por leche de la madre con enfermedad de Chagas. Mepra, Mision de Estudios de Patologia Regional Argentina 1936, 28:41-46.
20. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994, 127:151-162.
21. Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008, 14:542-550.
22. Dutra WO, da Luz ZM, Cançado JR, Pereira ME, Brigido-Nunes RM, Galvão LM, Colley DG, Brener Z, Gazzinelli G, Carvalho-Parra JF. Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol 1996, 18:579-585.
23. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, Lococo B, Barbieri G, Viotti RJ, Tarleton RL. Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004, 189:909-918.
24. Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 2011, 7:1184-1191.
25. Vázquez-Chagoyán JC, Gupta S, Garg NJ. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol 2011, 75:121-146.
26. Brener Z, Gazzinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 1997, 114:103-110.
27. Golgher D, Gazzinelli RT. Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity 2004, 37:399-409.
28. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 2003, 71:1185-1193.
29. Piaggio E, Roggero E, Pitashny M, Wietzerbin J, Bottasso OA, Revelli SS. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitol Res 2001, 87:539-547.
30. Revelli S, Le Page C, Piaggio E, Wietzerbin J, Bottasso O. Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. Clin Exp Immunol 1999, 118:271-277.
31. Camandaroba EL, Reis EA, Gonçalves MS, Reis MG, Andrade SG. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from highly resistant Colombian strain. Rev Soc Bras Med Trop 2003, 36:201-209.
32. Cançado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop 2002, 44:29-37.
33. Toledo MJ, Bahia MT, Veloso VM, Carneiro CM, Machado-Coelho GL, Alves CF, Martins HR, Cruz RE, Tafuri WL, Lana M. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruziclonal genotypes. J Antimicrob Chemother 2004, 53:1045-1053.
34. Olivieri BP, Cotta-De-Almeida V, Araujo-Jorge T. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+T-cell expansion and promotes resistance to reinfection. Antimicrob Agents Chemother 2002, 46:3790-3796.